Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502)

Journal of Medicinal Chemistry

Volumn 50, Issue 23, 2007, Pages 5557-5560

  Hariprakasha, Humcha K ^a   Kosakowska Cholody, Teresa ^a   Meyer, Colin ^b   Cholody, Wieslaw M ^a   Stinson, Sherman F ^a   Tarasova, Nadya I ^a   Michejda, Christopher J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Reata Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA; GEMCITABINE; IMIDAZOACRIDONE DERIVATIVE; NAPHTHALIMIDE DERIVATIVE; PROTEIN P53; RTA 502; UNCLASSIFIED DRUG; WMC 79;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN HCT116; COLON TUMOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG DNA BINDING; DRUG ELIMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS TUMOR; RAT; TUMOR GROWTH; TUMOR XENOGRAFT;

ACRIDONES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, NUDE; NAPHTHALIMIDES; NEOPLASM TRANSPLANTATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36149000928     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7009777     Document Type: Article

References (9)

1. Kamb, A.; Wee, S.; Lengauer, C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discovery 2007, 6, 115-120.
2. Sjoblom, T.; Jones, S.; Wood, L. D.; Parsons, D. W.; Lin, J.; Barber, T. D.; Mandelker, D.; Leary, R. J.; Ptak, J.; Silliman, N.; Szabo, S.; Buckhaults, P.; Farrell, C.; Meeh, P.; Markowitz, S. D.; Willis, J.; Dawson, D.; Willson, J. K.; Gazdar, A. F.; Hartigan, J.; Wu, L.; Liu, C.; Parmigiani, G.; Park, B. H.; Bachman, K. E.; Papadopoulos, N.; Vogelstein, B.; Kinzler, K. W.; Velculescu, V. E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274.
3. Cholody, W. M.; Hernandez, L.; Hassner, L.; Scudiero, D. A.; Djurickovic, D. B.; Michejda, C. J. Bisimidazoacridones and related compounds: New antineoplastic agents with high selectivity against colon tumors. J. Med. Chem 1995, 38, 3043-3052.
4. Cholody, W. M.; Kosakowska-Cholody, T.; Michejda, C. J. Bisimidazoacridones induce a potent cytostatic effect in colon tumor cells that sensitizes them to killing by UCN-01. Cancer Chemother. Pharmacol. 2001, 47, 241-249.
5. Kosakowska-Cholody, T.; Cholody, W. M.; Monks, A.; Woynarowska, B. A.; Michejda, C. J. WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway. Mol. Cancer Ther. 2005, 4, 1617-1627.
6. Tarasov, S. G.; Casas-Finet, J. R.; Cholody, W. M.; Michejda, C. J. Bisimidazoacridones: Effect of molecular environment on conformation and photophysical properties. Photochem. Photobiol. 1999, 70, 568-578.
7. Tarasov, S. G.; Casas-Finet, J. R.; Cholody, W. M.; Kosakowska-Cholody, T.; Gryczynski, Z. K.; Michejda, C. J. Bisimidazoacridones: 2. Steady-state and time-resolved fluorescence studies of their diverse interactions with DNA. Photochem. Photobiol. 2003, 78, 313-322.
8. Cholody, W. M.; Kosakowska-Cholody, T.; Hollingshead, M. G.; Hariprakasha, H. K.; Michejda, C. J. A new synthetic agent with potent but selective cytotoxic activity against cancer. J. Med. Chem. 2005, 48, 4474-4481.
9. Lehmstedt, K.; Schrader, K. Synthesis in the acridone series. Chem. Ber. 1937, 70, 1526.